4.6 Article

Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

Journal

BMC PUBLIC HEALTH
Volume 14, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1471-2458-14-813

Keywords

Influenza; Public health policy; Vaccines and immunization; Modeling; Epidemiology

Funding

  1. Sanofi Pasteur MSD
  2. Sanofi Pasteur
  3. Novartis Vaccines Diagnostics AG
  4. GlaxoSmithKline
  5. Abbott

Ask authors/readers for more resources

Background: Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels. Methods: A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data. Results: Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza-related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional +(sic)190 to +(sic)226 million yearly, in vaccination target groups. Conclusions: Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial

Rosalind Hollingsworth, Arto Palmu, Stephanie Pepin, Martin Dupuy, Anju Shrestha, Jukka Jokinen, Ritva Syrjanen, Joshua Nealon, Sandrine Samson, Iris De Bruijn

Summary: This study aims to evaluate the relative effectiveness of high-dose quadrivalent influenza vaccine compared to standard-dose quadrivalent influenza vaccine in preventing cardio-respiratory hospitalizations in adults aged 65 years and older. The study is conducted by the Finnish Institute for Health and Welfare, enrolling over 120,000 participants over multiple influenza seasons for randomized allocation and follow-up for up to 11 months post-vaccination.

AMERICAN HEART JOURNAL (2021)

Editorial Material Immunology

Introductory paper: High-dose influenza vaccine Preface

Mia Diaco, Lee-Jah Chang, Bruce Seet, Corey A. Robertson, Ayman Chit, Monica Mercer, David P. Greenberg, Rosalind Hollingsworth, Sandrine I. Samson

Summary: The high-dose influenza vaccine is significant for older adults, providing a more effective prevention measure against influenza and promoting healthy aging.

VACCINE (2021)

Article Critical Care Medicine

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study

Ruvim Izikson, Daniel Brune, Jean-Sebastien Bolduc, Pierre Bourron, Marion Fournier, Tamala Mallett Moore, Aseem Pandey, Lucia Perez, Nessryne Sater, Anju Shrestha, Sophie Wague, Sandrine Samson

Summary: This study assessed the safety and immunogenicity of concomitant administration of high-dose quadrivalent influenza vaccine (QIV-HD) and mRNA-1273 vaccine booster in older adults. The results showed no safety concerns or immune interference in the coadministration group, supporting the recommendations for co-administration. The antibody responses to influenza and SARS-CoV-2 were similar between the coadministration and QIV-HD groups.

LANCET RESPIRATORY MEDICINE (2022)

Letter Biotechnology & Applied Microbiology

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years

J. Kevin Yin, Stephanie Pepin, Robertus van Aalst, Matthew M. Loiacono, Sandrine I. Samson

Summary: The article challenges the recommendation of high-dose influenza vaccine and criticizes the authors of inaccurate numbers-needed-to-vaccinate (NNV) calculation. It emphasizes the importance of preferential recommendation for vaccines preventing influenza/complications and considering the impact of vaccination within the context of disease burden. To address the threat of the COVID-19 pandemic, the article suggests implementing concomitant influenza/COVID-19 vaccination to reduce the burden of co-circulation of influenza and SARS-CoV-2 viruses and increase vaccine coverage as per the WHO mandate.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Article Health Care Sciences & Services

Influence of Digital Intervention Messaging on Influenza Vaccination Rates Among Adults With Cardiovascular Disease in the United States: Decentralized Randomized Controlled Trial

Nell J. Marshall, Jennifer L. Lee, Jessica Schroeder, Wei-Nchih Lee, Jermyn See, Mohammad Madjid, Mrudula R. Munagala, John D. Piette, Litjen Tan, Orly Vardeny, Michael Greenberg, Jan Liska, Monica Mercer, Sandrine Samson

Summary: This personalized, evidence-based digital intervention proved effective in increasing vaccination rates among individuals with high-risk cardiovascular diseases. White and Asian individuals were more likely to get vaccinated, while the intervention had less impact on people of color.

JOURNAL OF MEDICAL INTERNET RESEARCH (2022)

Article Immunology

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study

Jau-Yuan Chen, Szu-Min Hsieh, Shinn-Jang Hwang, Chiu-Shong Liu, Xiaoling Li, Marion Fournier, Ting-Yu Yeh, J. Kevin Yin, Sandrine Samson

Summary: This study evaluated the immunogenicity and safety of high-dose and standard-dose influenza vaccines in older adults in Taiwan. The results showed that the high-dose vaccine had higher immunogenicity for all four influenza strains compared to the standard-dose vaccine, and both vaccines had similar safety profiles.

VACCINE (2022)

Article Biotechnology & Applied Microbiology

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Xiaoqiang Liu, Juliana Park, Shengli Xia, Bin Liang, Shuangmin Yang, Yanxia Wang, Olga Syrkina, Nathalie Lavis, Shuzhen Liu, Chenyan Zhao, Jian Ding, Jieqiong Hu, Sandrine Samson, Iris A. de Bruijn

Summary: The safety and immunogenicity of the quadrivalent, split-virion influenza vaccine (Shz QIV) developed in China were assessed. The vaccine showed good tolerability and induced immune responses in different age groups, demonstrating non-inferiority against various strains of influenza virus.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Letter Immunology

Letter to editor regarding a review of MF59-adjuvanted influenza vaccine by Gartner et al

J. Kevin Yin, Rebecca C. Harris, Matthew M. Loiacono, Ayman Chit, Sandrine I. Samson

VACCINE (2023)

Article Cardiac & Cardiovascular Systems

Nationwide Utilization of Danish Government Electronic letter system for increasing inFLUenza vaccine uptake (NUDGE-FLU): Study protocol for a nationwide randomized implementation trial

Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Daniel Modin, Brian L. Claggett, Erica L. Dueger, Sandrine Samson, Matthew M. Loiacono, Lars Kober, Scott D. Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: The NUDGE-FLU trial aims to investigate the effectiveness of digitally delivered behavioral nudges in increasing influenza vaccination uptake among older adults. It has randomized 964,870 Danish citizens aged 65 years and above to receive either no nudge or one of 9 electronic letters leveraging different behavioral science strategies. The trial will provide important insights into effective communication strategies to maximize vaccination uptake among high-risk groups.

AMERICAN HEART JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial

Daniel Modin, Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Brian L. Claggett, Erica L. Dueger, Sandrine I. Samson, Matthew M. Loiacono, Lars Kober, Scott D. Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: Digital behavioral nudges, such as electronic letters, emphasizing the potential cardiovascular benefits of influenza vaccination and using a reminder letter strategy, were found to be effective in increasing influenza vaccine uptake among older adults both with and without cardiovascular disease.

CIRCULATION (2023)

Article Cardiac & Cardiovascular Systems

Electronic nudges to increase influenza vaccination uptake among patients with heart failure: A pre-specified analysis of the NUDGE-FLU trial

Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Daniel Modin, Brian L. Claggett, Erica L. Dueger, Sandrine Samson, Matthew M. Loiacono, Rebecca C. Harris, Lars Kober, Scott D. Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: This study analyzed the effects of two behavioral nudging letter strategies on influenza vaccination rates in patients with heart failure (HF). The results showed that the vaccination rate in HF patients was relatively low, but the behavioral nudging letter strategies were effective in increasing the vaccination rate and had no negative impact on the use of guideline-directed medical therapy (GDMT) in the long term.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Medicine, General & Internal

Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial

Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Daniel Modin, Brian L. Claggett, Erica L. Dueger, Sandrine Samson, Matthew M. Loiacono, Lars Kober, Scott Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: This study investigated whether behavioural nudges delivered via a governmental electronic letter system could increase influenza vaccination uptake among older adults in Denmark. The results showed that sending an electronic letter highlighting potential cardiovascular benefits of vaccination or sending repeated letters at randomisation and at day 14 significantly improved vaccination rates.

LANCET (2023)

Review Immunology

High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update

Jason K. H. Lee, Gary K. L. Lam, J. Kevin Yin, Matthew M. Loiacono, Sandrine I. Samson

Summary: This updated systematic review and meta-analysis assessed the relative performance of high-dose inactivated influenza vaccine (HD-IIV) and standard-dose influenza vaccines (SD-IIV) against influenza-associated outcomes in older adults (& GE;65 years). The analysis included studies conducted over 12 influenza seasons and showed that HD-IIV provided significantly better protection than SD-IIV against influenza-related outcomes. Subgroup analyses further demonstrated the consistent superiority of HD-IIV across different age groups and strains of influenza.

VACCINE: X (2023)

Article Medicine, Research & Experimental

Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Niklas Dyrby Johansen, Daniel Modin, Joshua Nealon, Sandrine Samson, Camille Salamand, Carsten Schade Larsen, Brian L. Claggett, Scott D. Solomon, Martin J. Landray, Gunnar H. Gislason, Lars Kober, Jens Ulrik Staehr Jensen, Pradeesh Sivapalan, Lasse Skafte Vestergaard, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: This study aims to investigate the feasibility of a pragmatic clinical trial in Denmark comparing high-dose and standard-dose influenza vaccines. The study utilizes existing vaccination infrastructure and the Danish nationwide health registries for data collection. The results will provide valuable insights for future vaccine trials and other interventions.

PILOT AND FEASIBILITY STUDIES (2022)

No Data Available